Publication:
Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission

Simple item page
dc.contributor.authorRutt Chuachoowongen_US
dc.contributor.authorNathan Shafferen_US
dc.contributor.authorWimol Siriwasinen_US
dc.contributor.authorPongsakdi Chaisilwattanaen_US
dc.contributor.authorNancy L. Youngen_US
dc.contributor.authorPhilip A. Mocken_US
dc.contributor.authorSanay Chearskulen_US
dc.contributor.authorNaris Waranawaten_US
dc.contributor.authorThongpoon Chaowanachanen_US
dc.contributor.authorJohn Karonen_US
dc.contributor.authorR. J. Simondsen_US
dc.contributor.authorTimothy D. Mastroen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherRajavithi Hospitalen_US
dc.contributor.otherThailand Ministry of Public Healthen_US
dc.contributor.otherHIV/AIDS Collaborationen_US
dc.contributor.otherCenters for Disease Control and Preventionen_US
dc.date.accessioned2018-09-07T09:22:25Z
dc.date.available2018-09-07T09:22:25Z
dc.date.issued2000-01-26en_US
dc.description.abstractHuman immunodeficiency virus (HIV) levels in cervicovaginal lavage (CVL) and plasma samples were evaluated in relation to perinatal transmission in a randomized placebo-controlled trial of brief antenatal zidovudine treatment. Samples were collected at 38 weeks' gestation from 310 women and more frequently from a subset of 74 women. At 38 weeks, after a 2-week treatment period, CVL HIV-1 was quantifiable in 23% and 52% of samples in the zidovudine and placebo groups, respectively (P < .001). The perinatal transmission rate was 28.7% among women with quantifiable CVL HIV-1 and high plasma virus levels (>10,000 copies/mL) and 1% among women without quantifiable CVL HIV-1 and with low plasma virus levels (P < .001). A 1-log increase in plasma HIV-1 increased the transmission odds 1.8 and 6.1 times (95% confidence interval, 0.9-3.5 vs. 2.4-15.4) for women with and without quantifiable CVL HIV-1, respectively (P = .03). CVL HIV-1 is an independent risk factor for perinatal HIV-1 transmission.en_US
dc.identifier.citationJournal of Infectious Diseases. Vol.181, No.1 (2000), 99-106en_US
dc.identifier.doi10.1086/315179en_US
dc.identifier.issn00221899en_US
dc.identifier.other2-s2.0-0242289041en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/26292
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0242289041&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleShort-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmissionen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0242289041&origin=inwarden_US

Files

Collections

Scopus 1991-2000